Novartis Challenger To Alexion Advances In Rare Kidney Disease
Ultomiris Head-to-Head Planned
First-in-class iptacopan could help Novartis expand into kidney disease, and take on Alexion’s blockbuster rare disease franchise.
You may also be interested in...
While the sector is gripped by fears that overly zealous anti-competition regulators pose a threat to future M&A biopharma deals, AstraZeneca's acquisition of Alexion has sauntered through the US FTC's review. Its CFO Marc Dunoyer tells Scrip why the company is not surprised.
Interview: delivering on its US business strategy during the COVID-19 pandemic has required a focus on communication, according to Calliditas CEO Renee Aguiar-Lucander.
Key investors have pledged more patience in CEO Walmsley’s turnaround but they will be expecting a convincing vision of the future, more dynamic, GSK.